2018年5月4日上午，由重点实验室主办的“彩云医药讲坛”2018年第7-8期在昆明动物研究所举行，主讲者为陈策实研究员邀请的来自日本Jichi Medical University的Ryozo Nagai教授和Hiroshi Nishino教授，以及来自英国University of Leicester的Toru Suzuki教授。
Ryozo Nagai教授首先为大家带来了题为“KLF transcription family plays key roles in the pathogenesis of complex disease”的学术报告。Nagai教授作为KLF5转录因子的发现者，首次报道了BTEB2基因（即Krüppel-like transcription factor 5，KLF5）作为DNA结合蛋白在血管平滑肌细胞诱导SMemb转录。Nagai教授系统讲述了他们利用基因敲除小鼠模型发现KLF5在心脏发育和疾病、脂肪代谢、肿瘤发生方面的研究工作。
Toru Suzuki教授为大家带来了题为“Role of KLF6 in the cardio vasculature and metabolism”的学术报告。Suzuki教授简要介绍了他所在的大学研究中心，以及首次发现KLF家族另一个转录因子KLF6在心血管的主动脉夹层和心肌纤维化的功能和分子机制，能够成为潜在的治疗靶点。另外，Suzuki教授还介绍了KLF5在组蛋白乙酰化和去乙酰化修饰，参与DNA损伤修复以及细胞凋亡。
最后Hiroshi Nishino教授为大家介绍了他的研究工作——Basic Research of Oncolytic Virus Therapy for Head and Neck Cancers。头颈癌作为一种预后较差的癌症亟需寻找新的治疗靶点和治疗。G47Δ作为第三代的HSV-1溶瘤病毒在临床上能高效治疗多种癌症，G47Δ联合抗EGFR的单克隆抗体Cetuximab治疗头颈癌将显著抑制皮下肿瘤的生长。
参加本次论坛的专家除了我所的陈策实、盛能印研究员之外，还有远道而来的河北医科大学温进坤、郑斌和詹红教授。大家对三位教授带来的精彩报告进行了热烈讨论。
（图一：听众在听报告）
（图二：三位教授作报告）
专家简介
报告人一：Ryozo Nagai
Prof. Ryozo Nagai served as a president of Jichi Medical University (aslo, emeritus professor from University of Tokyo). Dr. Nagai’s academic activities have been published in top journals such as Nat Med, Nat Commun, Cancer Res, Cell Metab and J Clin Invest. Throughout his research career he has been focusing on basic research for molecular and cellular mechanisms of cardiovascular remodeling. Besides this, his research covers wide range of translational research such as development of systems for acquisition of patient record from electronic health record for construction of large scale database. He is energetic and enthusiastic in his pursuit of academic medicine. He also serves on many important committees as a chair or a member which determine the direction of Japanese science, medical research and medical care system.
报告人二：Toru Suzuki
Toru Suzuki is Professor/Chair of Cardiovascular Medicine at the University of Leicester (United Kingdom). Professor Suzuki is a specialist in cardiology and has a clinical appointment as Honorary Consultant Cardiologist in the University Hospitals of Leicester National Health System (NHS) Trust’s Glenfield Hospital which is one of the UK’s and Europe’s main cardiac specialist hospitals where he is responsible for the UK’s first aortic/vascular cardiology service. As an academic, Professor Suzuki has an h-factor of 47 (March 2018) with over 150 publications, such as Nature Reviews Disease Primers, Heart, Cardiovasc Res, Nat Commun and Circulation. Leads a cardiovascular translational research group within the Department of Cardiovascular Sciences at the University of Leicester which links with the activities of the National Institute of Health Research (NIHR) Biomedical Research Centre at the University. With precision medicine as a major theme, Professor Suzuki leads the phenomics activities focused on translational proteomics and metabolomics at world leading levels. He retains ties with the Far East with honorary professorships in Japan and in China.
报告人三：Hiroshi Nishino
Prof. Hiroshi Nishino is from Department of Otolaryngology-Head and Neck Surgery, Jichi Medical University. Dr. Nishino is a top leader of head and neck cancer treatments in Japan. His academic carrier has been known through his many high-quality publications, such as Annals of surgical oncology, SpringerPlus, SpringerPlus and BMC molecular biology. He is a member of American Society of Clinical Oncology, the Japanese Cancer Association, and Japan Society of Clinical Oncology. He has been focusing on clinical research for head and neck cancer. His research also covers wide range of translational research such as immunotherapy and oncolytic virus therapy of head and neck cancer. He serves on many important committees as a chair or a member which determine the direction of Japanese oto-rhino-laryngological society, medical research and international relationship.
